Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm

NCT05879055 is registered in ClinicalTrials.gov with Biotheus Inc. as lead sponsor.

NCT NCT05879055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm
Lead sponsor
Biotheus Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 17, 2023
Completion date
January 1, 2028
Enrollment
31 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine neoplasm